Back to top
more

Solventum Corporation (SOLV)

(Delayed Data from NYSE)

$90.95 USD

90.95
1,034,048

-0.11 (-0.12%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $90.94 -0.01 (-0.01%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?

by Zacks Equity Research

Here is how Solventum (SOLV) and Cronos Group (CRON) have performed compared to their sector so far this year.

Zacks Equity Research

SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio

by Zacks Equity Research

Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.

Zacks Equity Research

BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing

by Zacks Equity Research

BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.

Zacks Equity Research

HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency

by Zacks Equity Research

Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.

Mark Vickery headshot

Top Stock Reports for Alphabet, Roche & RTX

by Mark Vickery

Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.

Zacks Equity Research

BDX Unveils Portable PureWick System for On-the-Go Incontinence Care

by Zacks Equity Research

BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Zacks Equity Research

STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics

by Zacks Equity Research

Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.

Zacks Equity Research

SOLV vs. DHR: Which Stock Is the Better Value Option?

by Zacks Equity Research

SOLV vs. DHR: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Zacks Equity Research

Solventum (SOLV) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.